A follow-up meta-analysis looking at 25 case-control studies with a total of over 145,000 patients confirmed the increased risk for prostate cancer in HOXB13 G84E mutant carriers (OR 3.248; 95% CI, 2.313–4.560; p < 0.001) [68]. This evidence concerns the gene HOXB13 and prostate carcinoma.